1-ethylphenoxathiin 10,10-dioxide is a chemical compound with the formula C14H14O3S. It is a white solid at room temperature.
**Importance in Research:**
**1. Anti-Cancer Properties:**
1-ethylphenoxathiin 10,10-dioxide has demonstrated promising anti-cancer activity in various studies. It has been shown to:
* **Inhibit the growth of cancer cells** in vitro and in vivo.
* **Induce apoptosis (programmed cell death)** in cancer cells.
* **Interfere with the signaling pathways** that promote cancer cell growth and survival.
**2. Anti-Inflammatory Properties:**
* **Reduce inflammation** by inhibiting the production of pro-inflammatory cytokines.
* **Potentially useful for treating inflammatory conditions** like arthritis, asthma, and inflammatory bowel disease.
**3. Anti-Bacterial Properties:**
* **Exhibits antimicrobial activity** against various bacteria, including drug-resistant strains.
**4. Neuroprotective Properties:**
* **May protect neurons from damage** caused by oxidative stress and neurodegenerative diseases.
**5. Potential for Drug Development:**
* Its diverse pharmacological properties have led to significant research interest in its potential as a drug candidate for various diseases.
**6. Chemical Probe for Research:**
* 1-ethylphenoxathiin 10,10-dioxide can serve as a chemical probe for studying biological processes, particularly those related to cancer and inflammation.
**Current Research and Future Directions:**
Research on 1-ethylphenoxathiin 10,10-dioxide continues to explore its potential therapeutic applications. Studies are ongoing to:
* **Optimize its pharmacological properties** through chemical modifications.
* **Develop safe and effective drug delivery systems** for clinical use.
* **Evaluate its efficacy in pre-clinical and clinical trials** for specific diseases.
Overall, 1-ethylphenoxathiin 10,10-dioxide is a promising compound with significant potential for the development of new drugs for the treatment of cancer, inflammation, and other diseases. Its unique structure and diverse biological activities make it an important focus of research in medicinal chemistry and pharmacology.
1-ethylphenoxathiin 10,10-dioxide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 126111 |
CHEMBL ID | 66225 |
SCHEMBL ID | 3897015 |
MeSH ID | M0204786 |
Synonym |
---|
CHEMBL66225 , |
1-ethylphenoxathiine 10,10-dioxide |
1-ethyl-phenoxathiine 10,10-dioxide |
bdbm50009741 |
phenoxathiin, 1-ethyl-,10,10-dioxide |
134476-36-1 |
1-ethylphenoxathiin 10,10-dioxide |
unii-v8y35iom23 |
v8y35iom23 , |
bw-1370u87 |
phenoxathiin, 1-ethyl-, 10,10-dioxide |
SCHEMBL3897015 |
HQSRQKBSOOZLHH-UHFFFAOYSA-N |
DTXSID70158729 |
AKOS040748073 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0583 | 0.0007 | 1.9798 | 12.5000 | AID126050; AID126057 |
Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | Ki | 0.0100 | 0.0019 | 0.5533 | 4.8000 | AID126213 |
Amine oxidase [flavin-containing] A | Homo sapiens (human) | Ki | 0.0100 | 0.0019 | 2.3797 | 10.0000 | AID125562 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
biogenic amine metabolic process | Amine oxidase [flavin-containing] A | Homo sapiens (human) |
positive regulation of signal transduction | Amine oxidase [flavin-containing] A | Homo sapiens (human) |
dopamine catabolic process | Amine oxidase [flavin-containing] A | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
protein binding | Amine oxidase [flavin-containing] A | Homo sapiens (human) |
primary amine oxidase activity | Amine oxidase [flavin-containing] A | Homo sapiens (human) |
aliphatic amine oxidase activity | Amine oxidase [flavin-containing] A | Homo sapiens (human) |
monoamine oxidase activity | Amine oxidase [flavin-containing] A | Homo sapiens (human) |
flavin adenine dinucleotide binding | Amine oxidase [flavin-containing] A | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
mitochondrion | Amine oxidase [flavin-containing] A | Homo sapiens (human) |
mitochondrial outer membrane | Amine oxidase [flavin-containing] A | Homo sapiens (human) |
cytosol | Amine oxidase [flavin-containing] A | Homo sapiens (human) |
mitochondrion | Amine oxidase [flavin-containing] A | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (33.33%) | 5.53% |
Reviews | 1 (16.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 3 (50.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |